Q&A: Eurofins' Bruno Poddevin on Deciding When to 'Industrialize' Next-Gen Sequencing | GenomeWeb

PhotoPoddevin2.jpgName: Bruno Poddevin
Age: 47
Position: Senior vice president, genomic services, Eurofins Group, since 2008
Experience and Education:
Various positions at Eurofins (CEO of MWG Biotech, CEO of Eurofins Medigenomix/MWG Biotech, CEO of Operon Biotechnologies/Eurofins Medigenomix/MWG Biotech), 2005-2008

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.